<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE nitf SYSTEM "http://www.nitf.org/IPTC/NITF/3.3/specification/dtd/nitf-3-3.dtd">
<nitf change.date="June 10, 2005" change.time="19:30" version="-//IPTC//DTD NITF 3.3//EN">
  <head>
    <title>Vivigen Inc. reports earnings for Qtr to June 30</title>
    <meta content="11" name="publication_day_of_month"/>
    <meta content="7" name="publication_month"/>
    <meta content="1990" name="publication_year"/>
    <meta content="Wednesday" name="publication_day_of_week"/>
    <meta content="Financial Desk" name="dsk"/>
    <meta content="4" name="print_page_number"/>
    <meta content="D" name="print_section"/>
    <meta content="1" name="print_column"/>
    <meta content="Business" name="online_sections"/>
    <docdata>
      <doc-id id-string="367275"/>
      <doc.copyright holder="The New York Times" year="1990"/>
      <identified-content>
        <classifier class="indexing_service" type="descriptor">COMPANY REPORTS</classifier>
        <classifier class="online_producer" type="types_of_material">Statistics</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Business</classifier>
        <classifier class="online_producer" type="general_descriptor">Company Reports</classifier>
        <classifier class="online_producer" type="general_descriptor">Corporations</classifier>
      </identified-content>
    </docdata>
    <pubdata date.publication="19900711T000000" ex-ref="http://query.nytimes.com/gst/fullpage.html?res=9B05E7D6143BF932A25754C0A966958260" item-length="119" name="The New York Times" unit-of-measure="word"/>
  </head>
  <body>
    <body.head>
      <hedline>
        <hl1>Vivigen Inc. reports earnings for Qtr to June 30</hl1>
      </hedline>
    </body.head>
    <body.content>
      <block class="lead_paragraph">
        <p>LEAD:</p>
        <p>*3*** COMPANY REPORTS **</p>
        <p>*3* Vivigen Inc. (OTC)</p>
        <p>Qtr to June 30</p>
        <p>1990</p>
        <p>1989</p>
        <p>Revenue</p>
        <p>2,881,400</p>
        <p>2,262,400</p>
        <p>Net inc</p>
        <p>201,100</p>
        <p>496,000</p>
        <p>Share earns</p>
        <p>.08</p>
        <p>.20</p>
        <p>6mo rev</p>
        <p>5,788,900</p>
        <p>4,159,900</p>
        <p>Net inc</p>
        <p>487,300</p>
        <p>849,200</p>
        <p>Share earns</p>
        <p>.19</p>
        <p>.35</p>
        <p>The company said the decline in earnings, which began in the third quarter of 1989, was largely due to development of its new molecular testing capability and is now over.</p>
      </block>
      <block class="full_text">
        <p>LEAD:</p>
        <p>*3*** COMPANY REPORTS **</p>
        <p>*3* Vivigen Inc. (OTC)</p>
        <p>Qtr to June 30</p>
        <p>1990</p>
        <p>1989</p>
        <p>Revenue</p>
        <p>2,881,400</p>
        <p>2,262,400</p>
        <p>Net inc</p>
        <p>201,100</p>
        <p>496,000</p>
        <p>Share earns</p>
        <p>.08</p>
        <p>.20</p>
        <p>6mo rev</p>
        <p>5,788,900</p>
        <p>4,159,900</p>
        <p>Net inc</p>
        <p>487,300</p>
        <p>849,200</p>
        <p>Share earns</p>
        <p>.19</p>
        <p>.35</p>
        <p>The company said the decline in earnings, which began in the third quarter of 1989, was largely due to development of its new molecular testing capability and is now over.</p>
        <p>*3*** COMPANY REPORTS **</p>
        <p>*3* Vivigen Inc. (OTC)</p>
        <p>Qtr to June 30</p>
        <p>1990</p>
        <p>1989</p>
        <p>Revenue</p>
        <p>2,881,400</p>
        <p>2,262,400</p>
        <p>Net inc</p>
        <p>201,100</p>
        <p>496,000</p>
        <p>Share earns</p>
        <p>.08</p>
        <p>.20</p>
        <p>6mo rev</p>
        <p>5,788,900</p>
        <p>4,159,900</p>
        <p>Net inc</p>
        <p>487,300</p>
        <p>849,200</p>
        <p>Share earns</p>
        <p>.19</p>
        <p>.35</p>
        <p>The company said the decline in earnings, which began in the third quarter of 1989, was largely due to development of its new molecular testing capability and is now over.</p>
        <p>The company also said it began offering cystic fibrosis testing at the end of the most recent quarter, marking the first commercialization of its molecular genetic laboratory. The company expects that most of its future growth will come from this laboratory.</p>
      </block>
    </body.content>
  </body>
</nitf>
